Drug Eluting Balloon Market Share, Growth & Forecast by 2034

Drug Eluting Balloon Market Size and Forecasts (2021–2034), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage : by Product (Coronary Drug-eluting Balloon, Peripheral Drug-eluting Balloon, Other Products); Technology (FreePac, TransPac, EnduraCoat, Other Technologies); End Users (Hospitals, Ambulatory Surgical Centers, Other End Users); and Geography (North America, Europe, Asia Pacific, and South and Central America)

Historic Data: 2021-2024 | Base Year: 2025 | Forecast Period: 2026-2034
  • Status : Data Released
  • Report Code : TIPRE00040831
  • Category : Life Sciences
  • No. of Pages : 150
  • Available Report Formats : pdf-format excel-format
  • Last update date : May 26, 2026
Drug Eluting Balloon Market Share, Growth & Forecast by 2034
Report Date: May 26, 2026   |   Report Code: TIPRE00040831 Email: sales@theinsightpartners.com

2025 Market Size

US$ 714.69 Mn

Base year value

2034 Forecast

US$ 1,377.8 Mn

Projected by 2034

CAGR 2026-2034

8.55 %

Growth rate

Addressable Market

US$ 9,913.08 Mn

(2026-2034)

The Drug Eluting Balloon Market size is expected to reach US$ 1,377.8 Million by 2034 from US$ 714.69 Million in 2025. The market is estimated to record a CAGR of 8.55% from 2026 to 2034.

The report is segmented By Product (Coronary Drug-eluting Balloon, Peripheral Drug-eluting Balloon, and Other Products (Renal/urology)), Technology (FreePac, TransPac, EnduraCoat, and Other Technologies), End Users (Hospitals, Ambulatory Surgical Centers, and Other End Users). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.

Purpose of the Report

The report Drug Eluting Balloon Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:

  1. Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
  2. Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
  3. Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.

Drug Eluting Balloon Market Segmentation Product

  1. Coronary Drug-eluting Balloon
  2. Peripheral Drug-eluting Balloon
  3. Other Products

Technology

  1. FreePac
  2. TransPac
  3. EnduraCoat
  4. Other Technologies

End Users

  1. Hospitals
  2. Ambulatory Surgical Centers
  3. Other End Users

Market Research Highlights

  • Global market for Drug Eluting Balloon was valued at US$ 714.69 Million in 2025
  • Annual market size is expected to reach US$ 1,377.80 Million by 2034
  • Total addressable market (TAM) during 2026-2034 is projected to reach approximately US$ 9,913.08 Million
  • Market is anticipated to register a CAGR of 8.55% during the forecast period
  • The United States represents a key market, supported by Increasing Prevalence of Cardiovascular Diseases, Advancements in Balloon Technology, Minimally Invasive Procedures Preference, as well as evolving industry dynamics
  • Market analysis covers North America, Europe, Asia-Pacific, South and Central America, Middle East and Africa, with growth evaluated across the forecast period
  • Market opportunities such as Emerging Markets Adoption, Growth in Home Healthcare, Partnerships and Collaborations with Hospitals are expected to influence market dynamics and addressable market
  • Report profiles industry participants, including Medtronic PLC, Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, Koninklijke Philips NV, Cook Group Incorporated, Biotronik, B. Braun Melsungen AG, SurModics Inc., while analyzing competitive strategies and innovation developments
  • Source: The Insight Partners' analysis based on proprietary research, government publications, company annual reports, investor presentations, industry databases, and expert interviews.

● REPORT CUSTOMIZATION

Tailor This Report To Align With Your Specific Business Requirements

This report can be customized to align precisely with your business objectives, scope, and target markets. Customization options include tailored segmentation, geography, competitive analysis, and strategic insights to support informed decision-making.

Customize This Report →

WHAT YOU CAN ADJUST

  • Segmentations
  • Geography
  • Competitive Analysis
  • Language Preferences

Drug Eluting Balloon Market: Strategic Insights

drug-eluting-balloon-market
  • Get Top Key Market Trends of this report.
    This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Drug Eluting Balloon Market Growth Drivers

  1. Increasing Prevalence of Cardiovascular Diseases: The growing incidence of cardiovascular diseases, such as coronary artery disease (CAD) and peripheral artery disease (PAD), is driving the demand for drug-eluting balloons (DEBs). These balloons deliver localized drug therapy during angioplasty to prevent restenosis, making them highly effective in managing blocked arteries, improving patient outcomes, and reducing the need for repeat procedures.
  2. Advancements in Balloon Technology: Technological advancements in balloon design and drug delivery systems are fueling the growth of the DEB market. Innovations such as biodegradable polymers, improved drug formulations, and enhanced coating techniques are increasing the effectiveness of DEBs, ensuring better drug absorption and fewer complications. These improvements are expanding the clinical applications of DEBs in vascular interventions.
  3. Minimally Invasive Procedures Preference: The shift towards minimally invasive procedures is driving the adoption of drug-eluting balloons. These devices offer a non-surgical option for treating vascular diseases, providing faster recovery times, reduced risk of infection, and fewer complications compared to traditional surgery. This trend is encouraging healthcare professionals to use DEBs in both coronary and peripheral artery interventions.

Drug Eluting Balloon Market Future Trends

  1. Focus on Hybrid Therapies: A notable trend in the DEB market is the growing interest in hybrid therapies, which combine drug-eluting balloons with stents or other treatments. This approach is aimed at enhancing treatment efficacy, preventing restenosis, and reducing complications in complex vascular conditions. Hybrid therapies are gaining traction, especially in high-risk patients, for achieving long-term vascular patency.
  2. Expansion in Peripheral Artery Disease (PAD) Treatment: While DEBs have been primarily used for coronary artery disease, there is a rising trend toward their application in peripheral artery disease (PAD) treatment. The growing recognition of PAD as a major health issue, coupled with the effectiveness of DEBs in preventing restenosis in peripheral arteries, is driving the expansion of DEB usage beyond coronary applications.
  3. Regulatory Approvals and Clinical Advancements: Increasing regulatory approvals and positive clinical trial results for drug-eluting balloons are accelerating market growth. As more DEB products gain approval for different vascular applications, their adoption is expected to rise. The continuous improvement in clinical outcomes, coupled with favorable regulatory pathways, is fueling the widespread use of DEBs in treating various vascular diseases.

Drug Eluting Balloon Market Opportunities

  1. Emerging Markets Adoption: Emerging markets present a significant opportunity for the drug-eluting balloon market. As healthcare access improves in regions like Asia-Pacific, Latin America, and the Middle East, the demand for advanced cardiovascular treatments, including DEBs, is growing. Expanding into these markets provides opportunities for companies to introduce their products and address the rising burden of cardiovascular diseases.
  2. Growth in Home Healthcare: The increasing trend toward home healthcare offers an opportunity for the drug-eluting balloon market to innovate in patient follow-up care. With advancements in telemedicine and remote patient monitoring, companies can explore ways to integrate DEBs with home care programs, allowing for improved post-procedure management and reducing healthcare system burdens.
  3. Partnerships and Collaborations with Hospitals: There is an opportunity for drug-eluting balloon manufacturers to form strategic partnerships with hospitals and healthcare institutions. Collaborations can facilitate the integration of DEBs into standardized treatment protocols, allowing broader access to these devices in clinical settings. Such partnerships can drive greater adoption, improve patient outcomes, and foster innovation in DEB technology.

Drug Eluting Balloon Market Report Scope

Report Attribute Details
Market size in 2025 US$ 714.69 Million
Market Size by 2034 US$ 1,377.8 Million
Global CAGR (2026 - 2034) 8.55%
Historical Data 2021-2024
Forecast period 2026-2034
Segments Covered By Product
  • Coronary Drug-eluting Balloon
  • Peripheral Drug-eluting Balloon
  • Other Products
By Technology
  • FreePac
  • TransPac
  • EnduraCoat
  • Other Technologies
By End Users
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Medtronic PLC
  • Boston Scientific Corporation
  • Becton, Dickson and Company
  • Terumo Corporation
  • Koninklijke Philips NV
  • Cook Group Incorporated
  • Biotronik
  • B. Braun Melsungen AG
  • SurModics Inc.

Drug Eluting Balloon Market Players Density: Understanding Its Impact on Business Dynamics

The Drug Eluting Balloon Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

drug-eluting-balloon-market-cagr

Key Selling Points

  1. Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Drug Eluting Balloon Market, providing a holistic landscape.
  2. Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
  3. Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
  4. Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.

The research report on the Drug Eluting Balloon Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.


Frequently Asked Questions

Medtronic PLC, Boston Scientific Corporation, Becton, Dickson and Company, Terumo Corporation, Koninklijke Philips NV, Cook Group Incorporated, Biotronik, B. Braun Melsungen AG, SurModics Inc. are the some of the key market players operating in the drug eluting balloon market

Asia Pacific is estimated to grow at the highest CAGR of 8.55% from 2026 to 2034

The North America region accounts for highest revenue share drug eluting balloon market

The final report will duly include market size and projection estimates for all the segments from 2021 to 2034, along with a revenue share and compound annual growth rate (%) for the regional/country-wise market wherein 2021-2024 are the historic years, 2025 is considered to be the base year, and the forecast will be provided till 2034, along with CAGR of 8.55% from 2026 to 2034

The market is expected to grow at a CAGR of 8.55% from 2026 to 2034

Increasing prevalence of cardiovascular diseases and advancements in balloon technology are the major factors boosting the drug eluting balloon market growth
Mrinal Kerhalkar
Manager,
Market Research & Consulting

Mrinal is a seasoned research analyst with over 8 years of experience in Life Sciences Market Intelligence and Consulting. With a strategic mindset and unwavering commitment to excellence, she has built deep expertise in pharmaceutical forecasting, market opportunity assessment, and developing industry benchmarks. Her work is anchored in delivering actionable insights that empower clients to make informed strategic decisions.

Mrinal’s core strength lies in translating complex quantitative datasets into meaningful business intelligence. Her analytical acumen is instrumental in shaping go-to-market (GTM) strategies and uncovering growth opportunities across the pharmaceutical and medical device sectors. As a trusted consultant, she consistently focuses on streamlining workflow processes and establishing best practices, thereby driving innovation and operational efficiency for her clients.

  • Comprehensive Market Sizing and Forecast Analysis
  • Detailed Segmentation Analysis
  • In-Depth Market Dynamics Assessment
  • Regional and Country-Level Insights
  • Competitive Landscape and Company Benchmarking
  • Strategic Business Intelligence

Testimonials

Reason to Buy

  • Informed Decision-Making
  • Understanding Market Dynamics
  • Competitive Analysis
  • Identifying Emerging Markets
  • Customer Insights
  • Market Forecasts
  • Risk Mitigation
  • Boosting Operational Efficiency
  • Strategic Planning
  • Investment Justification
  • Tracking Industry Innovations
  • Aligning with Regulatory Trends
Sales Assistance
US: +1-646-491-9876
UK: +44-20-8125-4005
DUNS Logo
ISO Certified Logo
GDPR
CCPA